Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Regulatory News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 137.50
Bid: 135.00
Ask: 140.00
Change: 0.00 (0.00%)
Spread: 5.00 (3.704%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 137.50
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Faron’s financial calendar for 2022

21 Dec 2021 07:00

RNS Number : 2734W
Faron Pharmaceuticals Oy
21 December 2021
 

Faron Pharmaceuticals Ltd("Faron")

 

Faron's financial calendar for 2022

 

Company announcement, 21 December 2021 at 9.00 am (EET) / 07:00 AM (GMT) / 02:00 AM (EDT)

TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, announces the following dates for the Company's financial reporting in 2022:

 

25 March Financial statement release for the full year 2021 and

Annual Report 2021 including financial statements for the full year

25 August Half-year financial report for the period 1 January to 30 June 2022

 

The annual general meeting is planned to be held on Friday 22 April 2022. A separate stock exchange notice will be issued by Faron's board of directors to convene the meeting.

 

For more information please contact:

Media Contact

Faron Pharmaceuticals

Eric Van Zanten

Head of Communications

eric.vanzanten@faron.com

Investor.relations@faron.com

Phone: +1 (610) 529-6219

 

Investor Contact

Stern Investor Relations

Julie Seidel

julie.seidel@sternir.com

Phone: +1 (212) 362-1200

 

Cairn Financial Advisers LLP, Nomad

Sandy Jamieson, Jo Turner

Phone: +44 (0) 207 213 0880

 

 

 

Peel Hunt LLP, Broker

Christopher Golden, James Steel

Phone: +44 (0) 20 7418 8900

 

Sisu Partners Oy, Certified Adviser on Nasdaq First North

Juha Karttunen

Phone: +358 (0)40 555 4727

Jukka Järvelä

Phone: +358 (0)50 553 8990

 

Consilium Strategic Communications

Mary-Jane Elliott, David Daley, Lindsey Neville

faron@consilium-comms.com

Phone: +44 (0)20 3709 5700

 

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs caused by dysfunction of our immune system. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology, organ damage and bone marrow regeneration. Bexmarilimab, a novel anti-Clever-1 humanized antibody, is its investigative precision immunotherapy with the potential to provide permanent immune stimulation for difficult-to-treat cancers through targeting myeloid function. Currently in Phase I/II clinical development as a potential therapy for patients with untreatable solid tumors, bexmarilimab has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine is an investigational intravenous (IV) interferon beta-1a therapy for the treatment of acute respiratory distress syndrome (ARDS) and other ischemic or hyperinflammatory conditions. Traumakine is currently being evaluated in global trials as a potential treatment for hospitalized patients with COVID-19 and with the 59th Medical Wing of the US Air Force and the US Department of Defense for the prevention of multiple organ dysfunction syndrome (MODS) after ischemia-reperfusion injury caused by a major trauma. Faron is based in Turku, Finland. Further information is available at www.faron.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORURVURARUUUUA
Date   Source Headline
11th Jun 20207:00 amRNSFaron selected for EUR2.5 million grant from EIC
1st Jun 20207:00 amRNSMATINS Update
28th May 20207:00 amRNSFaron announces R&D Day to be held in June
20th May 20207:00 amRNSPublication in Intensive Care Medicine
18th May 20204:00 pmRNSResults of the Annual General Meeting
13th May 20201:00 pmRNSExercise of options
12th May 20206:00 pmRNSManagers’ transactions
11th May 202010:00 amRNSFaron receives grant from Business Finland
5th May 20207:00 amRNSClevegen manufacturing agreement
29th Apr 20201:15 pmRNSHolding(s) in Company
27th Apr 20202:45 pmRNSHolding(s) in Company
27th Apr 20207:00 amRNSTraumakine to be a part of WHO’s Solidarity trial
23rd Apr 20201:00 pmRNSUpdate on results of Placing and issue of equity
22nd Apr 20207:00 amRNSResult of placing and issue price
21st Apr 20204:45 pmRNSProposed Placing
15th Apr 202011:06 amRNSSecond Price Monitoring Extn
15th Apr 202011:00 amRNSPrice Monitoring Extension
14th Apr 20207:00 amRNSNotice of Annual General Meeting
3rd Apr 20202:45 pmRNSAGM to be postponed
1st Apr 20207:00 amRNSREMAP-CAP to study IFN beta-1a effect in COVID-19
30th Mar 20207:00 amRNSPart 1 of the MATINS Phase I/II Study Completed
26th Mar 202010:00 amRNSCorrection to Faron´s Annual Report 2019
25th Mar 20207:28 amRNSFaron´s Annual Report 2019 published
20th Mar 202011:30 amRNSNotice of Annual General Meeting
20th Mar 20207:00 amRNSFinal Results for the year ended December 31, 2019
19th Mar 20204:41 pmRNSSecond Price Monitoring Extn
19th Mar 20204:36 pmRNSPrice Monitoring Extension
12th Mar 20204:44 pmRNSSecond Price Monitoring Extn
12th Mar 20204:38 pmRNSPrice Monitoring Extension
9th Mar 20207:00 amRNSFDA accepts protocol for new Traumakine trial
5th Mar 20207:00 amRNSMATINS update
2nd Mar 20207:00 amRNSFaron to acquire AOC3 antagonist platform
26th Feb 20207:05 amRNSPrice Monitoring Extension
26th Feb 20207:01 amRNSSecond Price Monitoring Extn
26th Feb 20207:00 amRNSPrice Monitoring Extension
25th Feb 20202:05 pmRNSSecond Price Monitoring Extn
25th Feb 20202:00 pmRNSPrice Monitoring Extension
25th Feb 202011:00 amRNSPrice Monitoring Extension
24th Feb 20204:41 pmRNSSecond Price Monitoring Extn
24th Feb 20204:35 pmRNSPrice Monitoring Extension
18th Feb 202011:06 amRNSSecond Price Monitoring Extn
18th Feb 202011:00 amRNSPrice Monitoring Extension
18th Feb 20209:05 amRNSSecond Price Monitoring Extn
18th Feb 20209:00 amRNSPrice Monitoring Extension
6th Feb 20207:00 amRNSTraumakine update
27th Jan 20207:00 amRNSOvarian cancer selected as 2nd MATINS trial cohort
13th Jan 20207:00 amRNSDMC approves colorectal cancer cohort expansion
30th Dec 20199:30 amRNSUpdate on Traumakine drug substance manufacturing
12th Dec 20192:00 pmRNSPrice Monitoring Extension
11th Dec 20197:00 amRNSMatins Trial Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.